Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ:RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...

RGLS opened at $1.48 on Friday. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.00. The company has a market capitalization of $96.94 million, a price-to-earnings ratio of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...